Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR‐Preserved

Autor: Andrew J.S. Coats, Javed Butler, Hiroyuki Tsutsui, Wolfram Doehner, Gerasimos Filippatos, João Pedro Ferreira, Michael Böhm, Vijay K. Chopra, Subodh Verma, Matias Nordaby, Tomoko Iwata, Daisuke Nitta, Piotr Ponikowski, Faiez Zannad, Milton Packer, Stefan D. Anker

Publikováno v: Journal of Cachexia, Sarcopenia and Muscle, Vol 15, Iss 1, Pp 412-424 (2024)

Abstract Background Frailty is a severe, common co‐morbidity associated with heart failure (HF) with preserved ejection fraction (HFpEF). The impact of frailty on HFpEF outcomes may affect treatment choices in HFpEF. The impact of frailty on HFpEF

Externí odkaz: https://doaj.org/article/318bfe4e8c7643cebf686c262580d659

Clinical profile and one-year survival of patients with heart failure with reduced ejection fraction: The largest report from India

Autor: Vijay K. Chopra, Sanjay Mittal, Manish Bansal, Balbir Singh, Naresh Trehan

Publikováno v: Indian Heart Journal, Vol 71, Iss 3, Pp 242-248 (2019)

Background: India has one of the largest population of heart failure (HF) patients in the world; yet only limited information is available about HF in India. Methods: This observational study was performed at Medanta- The Medicity, a large, tertiary-

Externí odkaz: https://doaj.org/article/7f283411ab374c9d856be9f21fedea04

Health status across major subgroups of patients with heart failure and preserved ejection fraction

Autor: Tariq Jamal Siddiqi, Stefan D. Anker, Gerasimos Filippatos, João Pedro Ferreira, Stuart J. Pocock, Michael Böhm, Martina Brueckmann, Vijay K. Chopra, Tomoko Iwata, James Januzzi, Ileana L. Piña, Piotr Ponikowski, Michele Senni, Ola Vedin, Subodh Verma, Yuhui Zhang, Faiez Zannad, Milton Packer, Javed Butler

Publikováno v: European Journal of Heart Failure.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::998a9e45960fad5f8c227b23b3a01bec
https://doi.org/10.1002/ejhf.2831

Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction

Autor: Alice M, Jackson, Rasmus, Rørth, Jiankang, Liu, Søren Lund, Kristensen, Inder S, Anand, Brian L, Claggett, John G F, Cleland, Vijay K, Chopra, Akshay S, Desai, Junbo, Ge, Jianjian, Gong, Carolyn S P, Lam, Martin P, Lefkowitz, Aldo P, Maggioni, Felipe, Martinez, Milton, Packer, Marc A, Pfeffer, Burkert, Pieske, Margaret M, Redfield, Adel R, Rizkala, Jean L, Rouleau, Petar M, Seferović, Jasper, Tromp, Dirk J, Van Veldhuisen, Mehmet B, Yilmaz, Faiez, Zannad, Michael R, Zile, Lars, Køber, Mark C, Petrie, Pardeep S, Jhund, Scott D, Solomon, John J V, McMurray

Publikováno v: European Journal of Heart Failure, 24(3), 497-509. Wiley
Jackson, A M, Rørth, R, Liu, J, Kristensen, S L, Anand, I S, Claggett, B L, Cleland, J G F, Chopra, V K, Desai, A S, Ge, J, Gong, J, Lam, C S P, Lefkowitz, M P, Maggioni, A P, Martinez, F, Packer, M, Pfeffer, M A, Pieske, B, Redfield, M M, Rizkala, A R, Rouleau, J L, Seferović, P M, Tromp, J, Van Veldhuisen, D J, Yilmaz, M B, Zannad, F, Zile, M R, Køber, L, Petrie, M C, Jhund, P S, Solomon, S D, McMurray, J J V & PARAGON-HF Committees and Investigators 2022, ' Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction ', European Journal of Heart Failure, vol. 24, no. 3, pp. 497-509 . https://doi.org/10.1002/ejhf.2403

Aim: There is an association between heart failure with preserved ejection fraction (HFpEF) and insulin resistance, but less is known about the diabetic continuum, and in particular about pre-diabetes, in HFpEF. We examined characteristics and outcom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b2a3bc54fa5e92d9ecc85a2668abf4e
https://doi.org/10.1002/ejhf.2403

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial

Autor: Jan Oscarsson, Emily E Akin, Ali Javaheri, Diogo D.F. Moia, Russell Esterline, Fengming Tang, Gary G. Koch, Audes D. M. Feitosa, Robert Gordon, Samvel B. Gasparyan, Joan Buenconsejo, Cristiano P Jaeger, Weimar Kunz Sebba Barroso, Philip Ambery, Omar Mukhtar, Paulo Leães, Anna Maria Langkilde, Subodh Verma, Conrado R. Hoffmann Filho, Ronaldo V P Soares, Kensey Gosch, Lilia Nigro Maia, Michael Pursley, Otavio Berwanger, Michael E. Nassif, Sheryl L. Windsor, Mikhail Kosiborod, José Roberto Lazcano Soto, Felipe Martinez, Vijay K. Chopra, Remo H.M. Furtado, Matthew Aboudara, Fabio Serra Silveira, Alberto Fonseca, Vishnu Garla

Publikováno v: The Lancet. Diabetes & Endocrinology

Summary Background COVID-19 can lead to multiorgan failure. Dapagliflozin, a SGLT2 inhibitor, has significant protective benefits for the heart and kidney. We aimed to see whether this agent might provide organ protection in patients with COVID-19 by

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13309fb301d8f869f6b911b980626f4b
https://doi.org/10.1016/s2213-8587(21)00180-7